Document is current
Any future updates will be listed below
-
Authors
Yanagisawa, Takafumi https://orcid.org/0000-0002-7410-0712
Matsukawa, Akihiro https://orcid.org/0000-0002-3324-762X
Rajwa, Paweł https://orcid.org/0000-0003-4073-6584
Miszczyk, Marcin https://orcid.org/0000-0002-4375-0827
Fazekas, Tamás
Pradere, Benjamin https://orcid.org/0000-0002-7768-8558
Miyajima, Keiichiro
Enei, Yuki
Cormio, Angelo https://orcid.org/0000-0002-6897-7040
Dematteis, Alessandro
Soeterik, Timo
Okada, Atsuya
Kuruma, Hidetoshi
Lenzo, Nat
Shariat, Shahrokh F.
Miki, Kenta
Kimura, Takahiro https://orcid.org/0000-0002-5673-1553
- License Information
-
More Information
Article History
Received: 11 June 2025
Revised: 2 September 2025
Accepted: 24 September 2025
First Online: 8 October 2025
Competing interests
: Takahiro Kimura is a paid consultant/advisor of Astellas, Bayer, Janssen and Sanofi. Shahrokh F. Shariat received follows: Honoraria: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, Takeda, Consulting or Advisory Role: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Takeda, Speakers Bureau: Astellas, Astra Zeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, Takeda, The other authors declare no conflicts of interest associated with this manuscript.
